Plasma level of lipopolysaccharide-binding protein is indicative of acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.

International Journal of Hematology
Hai-ge YeXiao-Su Zhao

Abstract

Acute graft-versus-host disease (aGVHD) is the major cause of non-relapse mortality following allogeneic hematopoietic stem cell transplantation. To date, there are no consensus specific plasma biomarkers for aGVHD. We recently identified several candidates differentially expressed in aGVHD patients. Here, we have validated one such candidate: lipopolysaccharide-binding protein (LBP). We detected plasma LBP level by ELISA in 73 patients and performed correlation analysis with the progression and severity of aGVHD. We found that plasma LBP level increased during the period of aGVHD and decreased markedly as aGVHD was resolved. LBP level in patients with moderate aGVHD (25-50 % skin rash area of grade 1 and grade 2) was higher than in patients with no, little (skin rash area <25 % of grade 1), or severe aGVHD (grade 3-4). Higher LBP level indicated higher probability of aGVHD. Multivariate analysis showed that LBP level above 15000 ng/ml was significantly associated with an increased risk of aGVHD (HR 2.43; 95 % CI 1.29-4.58; P = 0.006). If LBP level exceeded 15000 ng/ml at d7 and d14 after HSCT, the subsequent probability of aGVHD increased markedly, especially at the time point of d14. There was no correlation between LBP level...Continue Reading

References

Jul 1, 1994·The Journal of Investigative Dermatology·K NonomuraS Hirose
Feb 27, 1999·Current Opinion in Immunology·R J Ulevitch, P S Tobias
Jan 23, 2003·The Journal of Immunology : Official Journal of the American Association of Immunologists·Anita C E VreugdenhilWim A Buurman
Jan 29, 2003·The Journal of Infectious Diseases·Laurent BlaironPierre-François Laterre
Nov 14, 2003·The Pediatric Infectious Disease Journal·Ofer LevyEva Guinan
Aug 30, 2008·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Jason E FoleyDaniel H Fowler
Oct 4, 2008·Blood·Sophie PaczesnyJames L M Ferrara
Nov 13, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert M DeanMichael R Bishop
Mar 14, 2009·Lancet·James L M FerraraErnst Holler
Apr 8, 2010·Science Translational Medicine·Sophie PaczesnyJames L M Ferrara
Jun 8, 2010·Molecular and Cellular Biochemistry·Haige YeXiaoshu Zhao

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.